Background And Aim: Measuring 6-thioguanine nucleotide (6-TGN) level is useful in optimizing dose of azathioprine (AZA) and monitoring for toxicity. Lower dose of AZA was suggested for maintenance of clinical remission in Asian patients than Caucasian patients with Crohn's disease (CD). However, the optimal 6-TGN threshold required in Asian patients is undetermined. Therefore, the aim of the current study is to explore the optimal 6-TGN threshold required in Asian patients with CD for maintenance of clinical remission.
Methods: A retrospective cohort study in a tertiary referral center recruited 252 CD patients. The primary endpoint was disease relapse. The levels of 6-TGN and AZA dose were compared in remission group and relapse group. Remission rate was compared across the increased 6-TGN level and dose range.
Results: Patients with 6-TGN range of 0-180.94 pmol/8 × 10 red blood cells (RBC) had lower remission rate compared with those with 180.94-255.50 pmol/8 × 10 RBC (P = 0.020). Quartile analysis showed that increasing 6-TGN level beyond 180 pmol/8 × 10 RBC produced negligible gain in rate of remission. Frequency of adverse events significantly increased in patients with 6-TGN level > 355 pmol/8 × 10 RBC (8.0% with 6-TGN > 355 pmol/8 × 10 RBC vs 2.7% with 6-TGN < 355 pmol/8 × 10 RBC, P = 0.035).
Conclusion: Our study suggested that optimal 6-TGN threshold required to maintain clinical remission in Chinese patients was 180-355 pmol/8 × 10 RBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jgh.14465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis.
Clin Ther
January 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:
Purpose: Mesalazine and thiopurines are important therapeutic agents for pediatric patients with ulcerative colitis (UC). Mesalazine, which may be administered in different forms depending on delivery mechanisms, can affect thiopurine metabolism, leading to increased 6-thioguanine nucleotides (6-TGN) levels. Therefore, when using these two drugs simultaneously, their interactions must be considered.
View Article and Find Full Text PDFTherapeutic Agents and Patient Characteristics Affecting Metabolism of Thiopurines in Patients with Inflammatory Bowel Disease.
Fukushima J Med Sci
January 2025
Department of Coloproctology and Gastroenterology, Aizu Medical Center Fukushima Medical University.
Objectives: In inflammatory bowel disease therapy, thiopurines have been essential. However, several reports have investigated factors affecting thiopurine metabolism to date. This study investigated factors affecting intracellular concentrations of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) in a real-world setting.
View Article and Find Full Text PDF6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.
Intern Med J
November 2024
Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Article Synopsis
- Thiopurine co-therapy with anti-TNFα agents improves drug levels and reduces the chance of developing antibodies in patients with inflammatory bowel disease (IBD).* -
- A study analyzed the relationship between 6-thioguanine nucleotide (6-TGN) levels and anti-TNFα levels among IBD patients from 2015 to 2021, showing a significant link with infliximab but not adalimumab.* -
- The research identified optimal 6-TGN cut-off levels for effective therapeutic anti-TNFα levels, suggesting lower levels may suffice for treatment, particularly for infliximab.*
Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.
Clin Pharmacokinet
August 2024
Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Article Synopsis
- - The text discusses the use of thiopurine prodrugs like thioguanine (TG), azathioprine (AZA), and mercaptopurine (MP) in treating conditions such as leukemia and inflammatory bowel disease (IBD), highlighting the importance of measuring 6-thioguanine nucleotides (6-TGNs) for monitoring treatment, although high levels can lead to side effects like leukopenia.
- - It emphasizes the potential advantage of measuring DNA-incorporated thioguanine (DNA-TG) over 6-TGNs, as DNA-TG can account for genetic variations that affect drug metabolism, particularly in various ethnic populations.
- - A systematic review and meta-analysis
Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease.
Lupus Sci Med
January 2024
Department of Medicine, Duke University, Durham, North Carolina, USA.
Article Synopsis
- This study investigates the effects of pregnancy on the metabolism of azathioprine (AZA) and its metabolites in women with rheumatic diseases, focusing on 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN).
- It includes data from 37 pregnancies and 108 blood samples, finding stable levels of 6-TGN but elevated levels of 6-MMPN during pregnancy without associated liver issues.
- The research notes a potential link between metabolite levels, maternal disease activity, and improved neonatal outcomes, although the findings on significant changes in 6-TGN levels during pregnancy were inconclusive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!